Research programme: hormone based therapeutics - InnopharmaAlternative Names: IP 126
Latest Information Update: 30 Sep 2014
At a glance
- Originator InnoPharma Inc
- Class Hormones
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 25 Sep 2014 InnoPharma Inc has been acquired by Pfizer
- 13 Nov 2013 Preclinical trials in Undefined indication in USA (Injection, Ophthalmic)